Defendant:	Abraxis Bioscience, Inc. (formerly known as Astrazeneca Phar, Actavis Group hf., Actavis Totowa LLC, Actavis, Inc., App Pharmaceuticals, Inc., Caraco Pharmaceutical Laboratories, Limited, Mustafa Nevzat Ilac Sanayii A.S. (aka MN Pharmaceuticals), Par Pharmaceutical Companies, Inc., Par Pharmaceutical, Inc., Sun Pharmaceutical Industries, Limited and W.C. Heraeus GMBH
Defendant-Appellee:	Barr Laboratories, Inc., Fresenius Kabi Oncology Plc (f/k/a Dabur Oncology plc), Fresenius Kabi Pharma Limited (f/k/a/ Dabur Pharma Limited), Hospira Australia Pty Ltd, Hospira, Inc., Mayne Pharma (USA) Inc. (fka Faulding Pharmaceutical Co.), Mayne Pharma Limited, Pharmachemie B.V., Pliva-Lachema A.S., Sandoz, Inc., Teva Parenteral Medicines, Inc. and Teva Pharmaceuticals USA, Inc.
Plaintiff-Appellant:	Debiopharm S.A., Sanofi-Aventis and Sanofi-Aventis U.S. LLC
Case Number:	09-1427
Filed:	June 30, 2009
Court:	U.S. Court of Appeals, Federal Circuit
Nature of Suit:	Other

Access additional case information on PACER

Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.